CD19 and acute lymphoblastic leukemia: Therefore, the current study objective was to generate and characterize a novel CD19-directed antibody therapeutic based on a humanized CD19-IgG1 antibody and fused with the apoptosis-inducing ligand TRAIL, in order to induce BCP-ALL-specific killing.